Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Lancet Oncol
; 23(8): 1044-1054, 2022 08.
Article
in En
| MEDLINE
| ID: mdl-35835135
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leiomyosarcoma
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Country of publication: